Alexion 4th-qtr profits beat estimates but sales miss

16 February 2017

Rare diseases specialist Alexion Pharmaceuticals (Nasdaq: ALXN) on Thursday reported fourth-quarter 2016 earnings of $93 million, and net income of 40.41 per share. Earnings per share, adjusted for one-time gains and costs, were $1.26, versus $1.04 per share in the fourth quarter of 2015.

The results surpassed Wall Street expectations. The average estimate of 15 analysts surveyed by Zacks Investment Research was for earnings of $1.23 per share. The company posted revenue of $831 million in the period, up 19%, which missed Street forecasts. 12 analysts surveyed by Zacks expected $836.7 million.

Total revenues for the full year of 2016 were $3.084 billion, an 18% increase compared to 2015. The negative impact of foreign currency on total revenue year over year was 3% or $74 million, net of hedging activities. EPS for the full year of 2016 was $4.62 per share compared with $4.65 per share for the full year of 2015.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK